Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China
Palisade Bio (NASDAQ:PALI) has received a Notice of Allowance from the China National Intellectual Property Administration for a patent covering PALI-2108, their lead product candidate. The patent, titled "Gut Microbiota-Activated PDE4 Inhibitor Prodrug," will extend into 2045 and covers composition of matter claims.
PALI-2108 is a first-in-class PDE4 inhibitor targeting the terminal ileum and colon for treating fibrostenotic Crohn's disease (FSCD) and ulcerative colitis (UC). The drug is currently being evaluated in a Phase 1b/2a clinical trial. The Chinese Inflammatory Bowel Disease market represents a significant opportunity, with forecasts approaching $1B in total revenues by 2030.
Palisade Bio (NASDAQ:PALI) ha ricevuto una Notifica di Concessione dall'Amministrazione Nazionale della Propriet脿 Intellettuale della Cina per un brevetto relativo a PALI-2108, il loro principale candidato farmaco. Il brevetto, intitolato "Prodrug inibitore PDE4 attivato dal microbiota intestinale", sar脿 valido fino al 2045 e copre rivendicazioni sulla composizione della sostanza.
PALI-2108 猫 un inibitore PDE4 di prima classe che agisce sull'ileo terminale e sul colon per il trattamento della malattia di Crohn fibrostenotica (FSCD) e della colite ulcerosa (UC). Il farmaco 猫 attualmente in fase di valutazione in uno studio clinico di fase 1b/2a. Il mercato cinese delle malattie infiammatorie intestinali rappresenta un'opportunit脿 significativa, con previsioni di ricavi totali che si avvicinano a 1 miliardo di dollari entro il 2030.
Palisade Bio (NASDAQ:PALI) ha recibido un Aviso de Concesi贸n por parte de la Administraci贸n Nacional de Propiedad Intelectual de China para una patente que cubre PALI-2108, su principal candidato a medicamento. La patente, titulada "Prof谩rmaco inhibidor de PDE4 activado por la microbiota intestinal", tendr谩 vigencia hasta 2045 y cubre reivindicaciones sobre la composici贸n de la materia.
PALI-2108 es un inhibidor PDE4 de primera clase que se dirige al 铆leon terminal y colon para tratar la enfermedad de Crohn fibroesten贸tica (FSCD) y la colitis ulcerosa (UC). El medicamento se encuentra actualmente en evaluaci贸n en un ensayo cl铆nico de fase 1b/2a. El mercado chino de enfermedades inflamatorias intestinales representa una oportunidad significativa, con previsiones de ingresos totales que se acercan a $1 mil millones para 2030.
Palisade Bio (NASDAQ:PALI)電� 欷戧淡 甑皜歆�鞁濎灛靷瓣淡鞙茧攵�韯� 欤茧牓 頉勲炒 鞎诫鞚� PALI-2108鞐� 雽�頃� 韸鬼棃 項堦皜 韱奠毳� 氚涭晿鞀惦媹雼�. "鞛ル偞 氙胳儩氍� 頇滌劚頇� PDE4 鞏奠牅鞝� 頂勲霌滊煭"鞚措澕電� 鞝滊鞚� 鞚� 韸鬼棃電� 2045云�旯岇 鞙犿毃頃橂┌, 氍检 臁办劚鞐� 甏�頃� 甓岆Μ毳� 韽暔頃╇媹雼�.
PALI-2108鞚� 靹湢順戩癌靹� 韥氤�(FSCD)瓿� 甓れ枒靹� 雽�鞛レ椉(UC) 旃橂毳� 鞙勴暣 毵愲嫧 須岇灔瓿� 瓴办灔鞚� 響滌爜鞙茧 頃橂姅 斓滌磮鞚� PDE4 鞏奠牅鞝�鞛呺媹雼�. 順勳灛 1b/2a靸� 鞛勳儊鞁滍棙鞚� 歆勴枆 欷戩瀰雼堧嫟. 欷戧淡 鞐检靹� 鞛レ頇� 鞁滌灔鞚� 2030雲勱箤歆� 齑� 毵れ稖鞚� 10鞏� 雼煬鞐� 鞚措ゼ 瓴冹溂搿� 鞓堨儊霅橃柎 靸侂嫻頃� 旮绊殞毳� 鞝滉车頃╇媹雼�.
Palisade Bio (NASDAQ:PALI) a re莽u un avis d'acceptation de l'Administration nationale de la propri茅t茅 intellectuelle de Chine pour un brevet couvrant PALI-2108, leur principal candidat m茅dicament. Le brevet, intitul茅 "Pro-drogue inhibiteur de PDE4 activ茅e par le microbiote intestinal", sera valable jusqu'en 2045 et couvre des revendications relatives 脿 la composition de la mati猫re.
PALI-2108 est un inhibiteur PDE4 de premi猫re classe ciblant l'il茅on terminal et le c么lon pour le traitement de la maladie de Crohn fibro-st茅notique (FSCD) et de la colite ulc茅reuse (UC). Le m茅dicament est actuellement 茅valu茅 dans un essai clinique de phase 1b/2a. Le march茅 chinois des maladies inflammatoires de l'intestin repr茅sente une opportunit茅 importante, avec des pr茅visions de revenus totaux approchant 1 milliard de dollars d'ici 2030.
Palisade Bio (NASDAQ:PALI) hat von der chinesischen Nationalen Beh枚rde f眉r geistiges Eigentum eine Zulassungsmitteilung f眉r ein Patent erhalten, das PALI-2108, ihren f眉hrenden Produktkandidaten, abdeckt. Das Patent mit dem Titel "Darmmikrobiota-aktivierter PDE4-Inhibitor-Prodrug" gilt bis 2045 und umfasst Anspr眉che auf die Zusammensetzung der Substanz.
PALI-2108 ist ein erstklassiger PDE4-Inhibitor, der auf das terminale Ileum und den Dickdarm abzielt und zur Behandlung der fibrostenotischen Morbus Crohn-Erkrankung (FSCD) und Colitis ulcerosa (UC) entwickelt wird. Das Medikament wird derzeit in einer Phase 1b/2a klinischen Studie getestet. Der chinesische Markt f眉r entz眉ndliche Darmerkrankungen stellt eine bedeutende Chance dar, mit Prognosen von nahezu 1 Milliarde USD Gesamtumsatz bis 2030.
- Patent protection in China extends until 2045, securing long-term market exclusivity
- Targeting Chinese IBD market with projected $1B revenue potential by 2030
- Multiple clinical milestones and data readouts expected in next 12-18 months
- First-in-class therapy status for PALI-2108 in FSCD and UC treatment
- Drug still in early clinical stages (Phase 1b/2a) with uncertain outcome
- Patent extensions subject to regulatory approval requirements
Insights
PALI secures patent protection in China for its novel IBD drug PALI-2108, extending IP rights through 2045 in a growing billion-dollar market.
Palisade Bio has secured a critical Notice of Allowance from China's intellectual property authority for its lead product candidate PALI-2108, a novel PDE4 inhibitor targeting inflammatory bowel diseases. This patent milestone extends protection until 2045 in one of the world's largest pharmaceutical markets, where IBD treatment revenues are projected to reach
The allowed patent covers composition of matter claims for PALI-2108, which is currently in Phase 1b/2a clinical trials for fibrostenotic Crohn's disease (FSCD) and moderate to severe ulcerative colitis (UC). This represents strong IP protection for PALI-2108's innovative mechanism as the first PDE4 inhibitor specifically designed to target the terminal ileum and colon.
China's pharmaceutical landscape presents significant growth opportunities for Palisade Bio. With a large population and increasing IBD diagnosis rates, securing IP protection in this territory enhances the company's commercial positioning and partnership potential. The extended protection timeline substantially increases the drug's potential lifetime value, creating a stronger foundation for future commercialization efforts.
The patent allowance comes at a strategic time as the company progresses through multiple clinical milestones. With data readouts expected in the next 12-18 months, this IP protection reduces competitor risk during this critical development phase. For a clinical-stage biotech company like Palisade, building a robust global patent estate is essential for maximizing asset value prior to potential partnerships or commercial launch.
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn鈥檚 disease (FSCD) and ulcerative colitis (UC), to address significant unmet medical needs
Inflammatory Bowel Disease is a large and growing market opportunity in China, with forecasts approaching
Carlsbad, CA, July 31, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (鈥淧alisade,鈥� 鈥淧alisade Bio,鈥� or the 鈥淐ompany鈥�), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the China National Intellectual Property Administration has issued a Notice of Allowance for a patent covering PALI-2108, the Company鈥檚 novel, locally-activated, terminal ileum and colon-targeted phosphodiesterase-4 B/D (PDE4 B/D) inhibitor being developed for fibrostenotic Crohn鈥檚 disease (FSCD) and moderate to severe ulcerative colitis (UC).
Once issued, the allowed patent titled, 鈥�Gut Microbiota-Activated PDE4 Inhibitor Prodrug,鈥� will cover claims on the composition of matter for PALI-2108 in China with a base patent term currently extending into 2045, subject to extension to account for time required to fulfill requirements for regulatory approval.
鈥淪trengthening the global intellectual property portfolio around PALI-2108 remains a priority as we continue advancing this first-in-class therapy for FSCD and UC,鈥� said J.D. Finley, Chief Executive Officer of Palisade Bio. 鈥淭his Notice of Allowance in China bolsters our ability to protect long-term value in one of the world鈥檚 largest and fastest-growing pharmaceutical markets, further supporting both our clinical and strategic objectives. We remain highly confident in the potential of PALI-2108 and are diligently executing on multiple near-term clinical milestones and expected data readouts in the next 12-18 months, each of which, if successful, would represent a major value inflection point.鈥�
The Company is currently evaluating PALI-2108 in a Phase 1b/2a clinical trial for the treatment of FSCD and UC. For more information about the Phase 1a/b clinical study, visit and reference identifier NCT06663605.
About Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to .
Forward Looking Statements
This communication contains 鈥渇orward-looking鈥� statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the safety and tolerability, PK and drug release characteristics of PALI-2108 based on the Company鈥檚 preclinical studies and preliminary data from the Company鈥檚 clinical studies and indications and anticipated benefits of PALI-2108. These forward-looking statements are based upon the Company鈥檚 current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company鈥檚 forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company鈥檚 clinical trials, the timing and success of preclinical studies and clinical trials conducted by the Company, the risk that prior results, such as signals of safety, activity, or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company鈥檚 product candidates in clinical trials focused on the same or different indications; and the Company鈥檚 ability to secure additional financing to fund future operations and development of its product candidates. Additional risks and uncertainties can be found in the Company鈥檚 Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 24, 2025, as well as the Company鈥檚 Quarterly Report on Form 10-Q, for the three-month period ended March 31, 2025, filed with the SEC on May 12, 2025. These forward-looking statements speak only as of the date hereof and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company鈥檚 expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
FAQ
What patent protection did Palisade Bio (PALI) receive in China for PALI-2108?
What is PALI-2108 being developed to treat?
What is the current development stage of PALI-2108?
What is the market potential for PALI-2108 in China?
How is PALI-2108 different from other treatments?
